Aravive Inc. (NASDAQ:ARAV), a late clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that it received a $6 million development milestone payment from its licensee, 3D Medicines Inc. This milestone is based on the initiation of the global Phase 3 platinum resistant ovarian cancer (PROC) clinical trial in China for the development of Aravive’s batiraxcept.
Blue Apron Holdings Q4 EPS $(0.93) Misses $(0.67) Estimate, Adj. EBITDA Loss $17.9M vs Loss $1.7M In Same Qtr. Last Year, Sales $107.01M Miss $110.00M Estimate
Blue Apron Holdings (NYSE:APRN) reported quarterly losses of $(0.93) per share which missed the analyst consensus estimate of $(0.67) by 38.81 percent. This is a 38.81 percent decrease over losses of $(0.67) per share
